Vaxart, Inc. 8-K

What Happened Vaxart, Inc. announced on April 23, 2026 that the Board of Directors appointed James B. Breitmeyer, M.D., Ph.D., to serve as a director effective immediately. The Board determined Dr. Breitmeyer meets its independence standards. Vaxart furnished a press release announcing the appointment (Exhibit 99.1).

Key Details

• Appointment date: April 23, 2026; Dr. Breitmeyer’s term runs until his successor is elected or earlier if he resigns or is removed.
• Current roles: Chief Executive Officer and director of Altay Therapeutics, Inc. (since Feb 2026) and Operating Partner at SOLVE FSHD (since Sep 2025).
• Past experience: CEO of Oncternal Therapeutics (Feb 2016–June 2025); senior roles at Bavarian Nordic, Zogenix, Cadence Pharmaceuticals, and Applied Molecular Evolution; clinical/academic roles at Dana-Farber and Harvard Medical School.
• Compensation & legal: He will receive standard non-employee director cash and equity compensation under Vaxart’s program and has entered the company’s standard indemnification agreement. No related-party transactions or family relationships were reported.

Why It Matters For investors, this is a board-level governance update — not a change to Vaxart’s executive management team or financial guidance. The appointment brings a seasoned biotech executive with extensive drug development, clinical and commercial experience to Vaxart’s board, which may strengthen oversight of development programs and corporate strategy. The filing contains no new financial data or operational commitments.